Extracorporeal Shockwave Therapy

Extracorporeal Shockwave Therapy consists of a series of high-energy percussions delivered to the affected area. These are sound waves, not electric waves, making the procedure a safe and non-invasive treatment option.

The therapy works through three primary mechanisms:

1. Metabolic Stimulation: It produces an inflammatory response that increases metabolic activity around the site of pain, accelerating the remodeling of dysfunctional tissues like tendons and muscles.

2. Physical Debridement: The waves can physically break down scar tissue and calcification.

3. Neurological Inhibition: Transmission of pain is diminished through the inhibition of specific pain receptors.

ESWT stimulates the body’s natural self-healing process, often resulting in an immediate reduction in pain and improved range of motion. For many patients, this therapy can eliminate the need for surgical intervention.

Clinical success is defined as at least a 75% reduction in pain within three months. Globally, success rates are greater than 80%. While short-term effects are common, the full long-term benefits may take 3 to 4 months to materialize.

Patients typically require three to six treatments, administered at one-week intervals. Each session involves approximately 2,000 shocks per area and lasts about 5 minutes. The cost per treatment is $150.

We recommend contacting your insurance provider to confirm the specific requirements of your coverage. Invoices are issued under Chiropody/Extracorporeal Shockwave Therapy.

You may experience discomfort 2 to 4 hours after treatment, which typically subsides within 24 hours (though it can last longer in rare cases). Even if you feel immediate relief, we recommend decreased activity for 48 hours. If pain persists, you may use Tylenol, but you must avoid ice and anti-inflammatory medications, as these interfere with the therapeutic inflammatory response triggered by the shockwave.

Minor side effects may include swelling, redness, bruising (haematomas), or petechiae. These generally subside within 5 to 10 days.

This treatment is not recommended for individuals with:

• Coagulation or circulatory disorders (e.g., thrombosis).

• Current use of anticoagulants (Heparin, Coumadin, etc.).

• Tumour diseases or carcinoma.

• Active infections or wounds in the target area.

• Pregnancy.

• Cortisone therapy within the 6 weeks prior to treatment.

• Children in active growth stages.